RxDoctor Payments Data

Kimberly Bibb, APRN

Nurse Practitioner · Fernandina Beach, FLNPI 1336542430

Payments from drug & device makers

$1,787in general payments, 2019–2025

Across 75 payments — averaging $23.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$412
  • Lilly USA, LLC$318
  • GSK$189
  • Astellas Pharma US Inc$182
  • Novo Nordisk$180
  • AbbVie$107
  • plus $399 from 10 others

What the payments were for

  • Food & beverage$1,787100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,787 in reported general payments places this provider in the 80th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$89,340
Medicare patients
358
Services billed
1,314

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide89$94,781
OzempicSemaglutide42$41,252
ProliaDenosumab17$29,646
EliquisApixaban26$21,168
JardianceEmpagliflozin12$13,667
TrulicityDulaglutide11$10,492
FarxigaDapagliflozin Propanediol11$8,231
SynthroidLevothyroxine Sodium39$3,886
Atorvastatin Calcium297$2,879
PremproEstrogen,con/M-Progest Acet12$2,754
Omeprazole114$2,427
Levothyroxine Sodium231$1,904
Rosuvastatin Calcium160$1,887
Ibandronate Sodium65$1,867
PaxlovidNirmatrelvir/Ritonavir13$1,429

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$318$105,273100 claims
Novo NordiskOzempic$180$41,25242 claims
AmgenProlia$15$29,64617 claims
PfizerEliquis, Prempro, Paxlovid$19$25,35151 claims
Boehringer IngelheimJardiance$65$13,66712 claims
AstraZenecaFarxiga$412$8,23111 claims
AbbVieSynthroid$107$3,88639 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Fernandina Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →